Annual report pursuant to Section 13 and 15(d)

ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)

v3.22.4
ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)
Aug. 19, 2019
USD ($)
Asset Purchase Agreement [Member] | TRImaran Pharma Inc [Member]  
Asset Acquisition [Line Items]  
Payment for purchase of assets $ 100,000
Liabilities assumed 68,500
Research and development costs 168,500
Contingent milestone payment obligation 3,400,000
WSU License Agreement [Member]  
Asset Acquisition [Line Items]  
Reimbursement of patent expenses 75,000
Contingent milestone payment obligation $ 3,400,000
Percentage of royalties payable to any third party for intellectual property rights 50.00%
Maximum percentage reduction of royalties payable 50.00%